Emerging targeted therapies for breast cancer.
Breast cancer is the most common neoplasia among women in the world. For the last few years there has been an increasing interest in the development of agents against molecular targets considered to be involved in the process of malignant transformation or tumor progression. Experimental data indicate that various intracellular signaling pathways may be activated or overexpressed in patients who have breast cancer. Targeted therapies against these pathways have recently become one of the most active and promising areas of development in oncology.
Arnedos
Monica
M
Breast Unit, Department of Medicine, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK. monica.arnedos@rmh.nhs.uk
Seidman
Andrew D
AD
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006360:Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D006360:Heat-Shock Proteins; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases